<DOC>
	<DOCNO>NCT02787876</DOCNO>
	<brief_summary>To evaluate efficacy safety pegteograstim chemotherapy-induced neutropenia child solid tumor</brief_summary>
	<brief_title>Pegteograstim Children With Solid Tumors</brief_title>
	<detailed_description>Children solid tumor experience neutropenia cytotoxic chemotherapy , usually receive granulocyte colony-stimulating factor ( G-CSF ) stimulate neutrophil recovery . However need daily injection G-CSF . Pegteograstim new formulation PEGylated recombinant human G-CSF analogue pegfilgrastim . In study , investigator aim evaluate efficacy safety pegteograstim chemotherapy-induced neutropenia child solid tumor .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Patients solid tumor undergo chemotherapy carboplatin , etoposide , doxorubicin , cyclophosphamide ( CEDC ) ifosfamide , carboplatin , etoposide ( ICE ) regimen Patients organ dysfunction ( creatinine &gt; 2mg/dL , ejection fraction &lt; 40 % severe arrhythmia/conduction disorder , severe organ dysfunction ) Hypersensitivity pegteograstim , protein originate Ecoli , pegfilgrastim , filgrastim latex . Patients bleed tendency subcutaneous injection avoid . Active infection infectious fever screen period . Genetic problem fructose tolerance . Patients participate clinical trial within 4 week enrollment . Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>